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Abstract
Background: The benefit of Ginkgo biloba has been discussed controversially. The aim of this review was to assess
the effects of Ginkgo biloba in Alzheimer’s disease as well as vascular and mixed dementia covering a variety of
outcome domains.
Methods: We searched MEDLINE, EMBASE, the Cochrane databases, CINAHL and PsycINFO for controlled trials of
ginkgo for Alzheimer’s, vascular or mixed dementia. Studies had to be of a minimum of 12 weeks duration with at
least ten participants per group. Clinical characteristics and outcomes were extracted. Meta-analysis results were
expressed as risk ratios or standardized mean differences (SMD) in scores.
Results: Nine trials using the standardized extract EGb761® met our inclusion criteria. Trials were of 12 to 52 weeks
duration and included 2372 patients in total. In the meta-analysis, the SMDs in change scores for cognition were in
favor of ginkgo compared to placebo (-0.58, 95% confidence interval [CI] -1.14; -0.01, p = 0.04), but did not show a
statistically significant difference from placebo for activities in daily living (ADLs) (SMD = -0.32, 95% CI -0.66; 0.03,
p = 0.08). Heterogeneity among studies was high. For the Alzheimer subgroup, the SMDs for ADLs and cognition
outcomes were larger than for the whole group of dementias with statistical superiority for ginkgo also for ADL
outcomes (SMD = -0.44, 95% CI -0.77; -0.12, p = 0.008). Drop-out rates and side effects did not differ between
ginkgo and placebo. No consistent results were available for quality of life and neuropsychiatric symptoms, possibly
due to the heterogeneity of the study populations.
Conclusions: Ginkgo biloba appears more effective than placebo. Effect sizes were moderate, while clinical
relevance is, similar to other dementia drugs, difficult to determine.
Background
The standardized Ginkgo biloba extract EGb 761® is one
of the most widely used herbal remedies for dementia
and cognitive impairment and remains one of the best
evaluated and characterized extracts [1]. Since 2000,
according to the current ATC-classification, Ginkgo
biloba special extract is listed in the group of anti-
dementia drugs together with cholinesterase inhibitors
and memantine. However, most efficacy and effective-
ness studies are small, sufferf r o mm e t h o d o l o g i c a ll i m -
itations and are subject to considerable controversy.
Recently, the discussion about the benefits of Ginkgo
biloba extracts for different indications has again been
revitalized after the publication of two major trials. One
study [2] with 176 participants could not demonstrate
any evidence of effectiveness of 120 mg Ginkgo biloba
in mild to moderate dementia. In addition, the Ginkgo
Evaluation of Memory (GEM) study [3] found no favor-
able effects of 240 mg EGb 761® for the prevention of
dementia onset in older people without or with only
mild cognitive impairment. Whereas the GEM trial was
large enough to prove the robust result of a lacking
effect of Ginkgo biloba in dementia prevention and
overall mortality in people without dementia [4], the
randomized controlled trial (RCT) of McCarney et al.
has been criticized due to methodological problems and
insufficient sample size [5,6].
Most previous reviews have shown inconsistent results
and fail to draw firm conclusions whether Ginkgo biloba
has patient-relevant benefits in people with a diagnosis
of dementia [7,8]. In the meantime, new studies have
been published. A major limitation of the available
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dementia. No subgroup analyses were performed [7]. As
no valid definition of cognitive impairment has been
used, and given the finding of differential effects of
other anti-dementia drugs on dementia and cognitive
impairment [9], it appears no longer reasonable to pool
these two indications. Furthermore, the uncertainty
regarding mild cognitive impairment (MCI) as a clinical
entity raises the question as to the scientific validity of
MCI trials. In addition, the German Health Technology
Assessment Institute IQWiG (Institute for Quality and
Efficiency in Health Care) published a favorable report
on the effectiveness of Ginkgo biloba, which was, how-
ever, limited to Alzheimer’s disease and contradicted the
Cochrane review [10]. Taking into account the overlap
between different types of dementia [11] and the limited
significance of dementia subtyping in routine use of
anti-dementia drugs, there is no clear evidence for sub-
stantial differences in the effectiveness of those drugs in
vascular or Alzheimer’s dementia. As most anti-demen-
tia drugs including ginkgo are prescribed without com-
prehensive assessment of the dementia subtype, and
given continuing high prescription rates of ginkgo to
people with an established dementia diagnosis in some
countries, we felt that further decision support is neces-
sary for this kind of routine use of the substance. There-
fore, we performed a systematic review on the effects of
Ginkgo biloba in Alzheimer’s disease as well as vascular
and mixed dementia covering a variety of outcome
domains.
Methods
Data sources
We used a sensitive search strategy based on Cochrane
and other systematic reviews in the field. We searched
the following databases: MEDLINE (January 1, 1966, to
August 2008), EMBASE (January 1, 1980 to August
2008), PsycINFO (January 1, 1982, to August 2008),
CINAHL (Cumulative Index to Nursing and Allied
Health Literature), the Cochrane Database of Systematic
Reviews, and the Cochrane Controlled Trials Register
(until Issue 3, 2008). The following search terms were
used for dementia (with * characterizing a wildcard, and
the items AND and OR being used as boolean func-
tions): dementia; (senile* AND dement*); Alzheimer*;
((cognit* OR memory* OR mental*) AND (decline OR
impair* OR los* OR deteriorat* OR diminish* OR insuf-
ficien* OR degenerat*)). The following search terms
were used for Ginkgo biloba: ginkgo; ginko; gingko; bilo-
balid*; tebonin; egb 761; li 1370. To identify clinical
trials, we used the following search terms: (clinical AND
trial*); random*; placebo*; (controlled AND trial*); (mul-
ticent* AND stud*); (comparative AND stud*); follow-
up; (research AND design). All search terms within the
indication (dementia), ginkgo biloba and clinical trials
section were searched individually in each database and
combined together using the “OR” boolean. The results
of each of the three sections were then combined by uti-
lizing the “AND” boolean. Furthermore, the reference
sections of systematic and narrative reviews were
screened for primary publications. In addition, the man-
ufacturer of EGb 761®, Dr. Willmar Schwabe GmbH &
Co. KG, Karlsruhe, Germany, was queried and informa-
tion was requested as needed.
Selection and study characteristics
We selected controlled clinical trials, with or without
randomization, assessing the effects of treating people
with a diagnosis of Alzheimer’s disease, vascular or
mixed dementia according to internationally valid diag-
nostic criteria, with a standardized Ginkgo biloba
extract. Further study inclusion criteria were the use of
an internationally accepted diagnostic for the dementia
diagnosis such as the International Classification of Dis-
eases (ICD) [12], the Diagnostic and Statistical Manual
of Mental Disorders (DSM) [13], the NINCDS-ADRDA
(National Institute of Neurological and Communicative
Disorders and Stroke, Alzheimer’s Disease and related
Disorders Association) [14], or the NINDS-AIREN cri-
teria (National Institute for Neurological Disorders and
Stroke and Association Internationale pour la Recherche
et l’Enseignement en Neurosciences) [15]; a minimum
treatment duration of 12 weeks; a minimum number of
participants of ten per group; and the availability of a
full-text publication. Exclusion criteria were studies with
a majority of people with specific types of non-vascular
and non-Alzheimer’s dementia, such as Lewy-body
dementia or dementia due to Parkinson’s disease; and a
publication language other than English, German,
French, Italian or Spanish.
Data extraction and critical appraisal of studies
Study selection and appraisal of studies were performed
independently by two researchers (SW and SR). Dis-
agreement was resolved by consensus. Information was
extracted via a standardized checklist included study
design, duration of the study, comparability of study
groups with respect to sex, age, baseline scores of cogni-
tive, psychopathological and activities of daily living
scales and clinical outcomes on different rating scales in
the following domains: cognition, activities of daily living
(ADLs), neuropsychiatric symptoms, patients’ quality of
life, response according to the studies’ definitions and
drop out rates due to side effects. The study and publi-
cation quality was assessed on the basis of whether the
following quality criteria had been adequately fulfilled:
randomization and allocation concealment, blinding of
patients and investigators, sample size estimation,
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cation of the intent-to-treat principle, relevant data
inconsistencies, and report of study funding. All clinical
outcomes were assessed in the intent-to-treat samples.
An intent-to-treat analysis was accepted when a last-
observation-carried forward analysis was performed, or
when no drop-outs occurred and all patients were
included in the evaluation.
The following rating scales were accepted for clinical
outcomes: (1) cognition: Alzheimer’s Disease Assess-
ment Scale, cognitive subscale (ADAS-cog) [16], Syn-
drom-Kurztest (SKT) [17]; (2) ADLs: GERRI [18],
Nürnberger Alters-Alltagsaktivitäten-Skala (NAA) and
Nürnberger Alters-Beobachtungsskala (NAB) [19],
GBS-ADL (Gottries-Bråne-Steen - Activities of daily
living scale) [20], ADL-IS (Alzheimer’sD i s e a s eA c t i v -
ities-of-Daily-Living International Scale) [21], (3) neu-
ropsychiatric symptoms: Geriatric Depression Scale
(GDS) [22], Hamilton Depression Rating Scale
(HAMD) [23], Montgomery Asberg Depression Rating
Scale (MADRS) [24] and Neuropsychiatric Inventory
(NPI) [25]; and (4) quality of life: Quality of Life in
Alzheimer’s Disease (QOL-AD) [26], DEMQOL-Proxy
(Quality of Life Questionnaire for people with demen-
tia, rated by caregivers) [27], PDS (Progressive Dete-
rioration Scale) [28]. In addition, we intended to pool
the response rates with response definitions as used in
the studies.
Statistical analysis
If feasible and meaningful, data were pooled by means
of meta-analysis. Effect measures presented in this pub-
lication were reported as Mantel Haenszel risk ratios
(RRs) including 95% confidence intervals (CIs) for binary
data. Effects on rating scales were expressed as standar-
dized mean differences (SMDs) with the 95% CIs, N and
p values. A random-effects model was used to calculate
a pooled effect estimate, because we expected consider-
able heterogeneity. When different dose levels were used
in different study arms, the study arm with the higher
dosage was chosen, and a sensitivity analysis was per-
formed. Further sensitivity analyses were performed for
type of dementia (Alzheimer’s dementia versus vascular
or mixed dementia) and exclusion of studies with a high
number of participants without dementia.
Statistical significance was assumed in case of p <
0.05. Heterogeneity of effect sizes was evaluated by the
I
2 statistic. An alpha error p < 0.05 and/or I
2 of at least
50% were taken as indicators of substantial heterogene-
ity of outcomes. In this case, we examined the effect of
removing single studies with special study designs on
the results and on the heterogeneity. If meta-analyses
were not possible, the results of individual studies are
presented. Meta-analyses were performed using Review
Manager, version 5 (The Cochrane Collaboration,
Oxford, England) for all calculations.
Role of funding source
Funding for this review was provided via an unrestricted
grant from Dr. Willmar Schwabe GmbH & Co. KG,
Karlsruhe, Germany.
Results
Study characteristics
Our literature search in MEDLINE, EMBASE, Cochrane,
PsycINFO and CINAHL yielded 754 clinical publica-
tions. An unpublished manuscript of one study (which
has been published meanwhile) could be identified via
the manufacturer request. Two further publications
were added after hand searching journals and reference
lists of papers, with one additional unpublished manu-
script being supplied by the manufacturer. On the
whole, 63 publications were included in the full-text
screening. 17 publications reporting nine individual stu-
dies, all using the standardized extract EGb 761®, met
our inclusion criteria (Figure 1). EGb 761® is a dry
extract from Ginkgo biloba leaves, extraction solvent:
acetone 60% (w/w). The extract is adjusted to 22.0-
27.0% ginkgo flavonoids, calculated as ginkgo flavone
glycosides and 5.0-7.0% terpene lactones consisting of
2.8-3.4% ginkgolides A, B, C and 2.6-3.2% bilobalid. It
contains less than 5 ppm ginkgolic acids. There was no
study with other ginkgo product that met our inclusion
criteria.
All included studies were randomized. The randomi-
zation procedure was rated as sufficient in all cases.
However, allocation concealment remained unclear in
three studies (table 1). All studies were described as
double-blind, although in four studies, it was not expli-
citly stated that the outcome assessment was blinded.
Eight studies were placebo-controlled [2,29-34], Ihl R,
Bachinskaya N, Korczyn AD, Tribanek M, Hoerr R,
Napryeyenko O: Efficacy and Safety of a Once-Daily
Formulation of Ginkgo biloba Extract EGb 761® in
Dementia with Neuropsychiatric Features. A Rando-
mized Controlled Trial, submitted], and one study was
a head-to-head trial with donepezil as comparison
group [35]. Overall, the methodological quality of the
included studies was moderate to good, with most stu-
dies using an intent-to-treat analysis which was judged
as adequate. Two studies were performed in Germany,
two in the USA, and two in Ukraine, whereas one
study was performed in Bulgaria, the Netherlands and
Great Britain, respectively. In total, 2372 patients were
included and treated. All studies included patients with
Alzheimer’s disease. Six studies included also patients
with vascular dementia [29,30], Ihl R, Bachinskaya N,
Korczyn AD, Tribanek M, Hoerr R, Napryeyenko O:
Weinmann et al. BMC Geriatrics 2010, 10:14
http://www.biomedcentral.com/1471-2318/10/14
Page 3 of 12Efficacy and Safety of a Once-Daily Formulation of
Ginkgo biloba Extract EGb 761® in Dementia with
Neuropsychiatric Features. A Randomized Controlled
Trial, submitted] or vascular dementia plus mixed
dementia [2,32,34], Ihl R, Bachinskaya N, Korczyn AD,
Tribanek M, Hoerr R, Napryeyenko O: Efficacy and
Safety of a Once-Daily Formulation of Ginkgo biloba
Extract EGb 761® in Dementia with Neuropsychiatric
Features. A Randomized Controlled Trial, submitted].
One study included a majority of participants with
age-associated memory impairment. This study was
subjected to sensitivity analysis [34]. All studies
included only patients with mild or moderate dementia
(table 2). Some studies did not include patients with
substantial neuropsychiatric or behavioral symptoms
[30,31,33,34,36], whereas in two studies, the presence
of depression or behavioral symptoms of moderate
intensity was an explicit inclusion criterion [[32], Ihl R,
Bachinskaya N, Korczyn AD, Tribanek M, Hoerr R,
Napryeyenko O: Efficacy and Safety of a Once-Daily
Formulation of Ginkgo biloba Extract EGb 761® in
Dementia with Neuropsychiatric Features. A Rando-
mized Controlled Trial, submitted]. Patients with
severe or uncontrolled somatic disorders were
excluded from all trials except one [2].
The 12-26 weeks outcomes of the studies for the
whole patient group together (Alzheimer’sd i s e a s e ,v a s -
cular dementia or mixed dementia) are presented in the
next section. We present the results within different
outcome domains. Furthermore, results are compared
with the 52-weeks outcomes of the only long-term
study [30]. Within the respective sections, we present
data from the subgroup of patients with Alzheimer’s dis-
ease. Analyses of other subgroups are reported sepa-
rately. For all outcomes, negative change scores indicate
an improvement.
Figure 1 Flow chart of study identification and selection.
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Cognition
In all included studies (n = 9), cognition was evaluated.
Three studies used the ADAS-cog [2,30,33], whereas in
five studies [32,34-36], Ihl R, Bachinskaya N, Korczyn
AD, Tribanek M, Hoerr R, Napryeyenko O: Efficacy and
Safety of a Once-Daily Formulation of Ginkgo biloba
Extract EGb 761® in Dementia with Neuropsychiatric
Features. A Randomized Controlled Trial, submitted],
the SKT and in one study [31], both outcomes scales
were used. Due to the superior sensitivity of the SKT in
mild to moderate dementia, we used the SKT for the
latter study. Change scores for ADAS-cog ranged from
-0.3 to 1.3 in the ginkgo groups and from 0.9 to 1.0 in
the placebo groups, whereas change scores for SKT ran-
ged from -3.2 to -0.8 in the ginkgo groups and from
-1.2 to 1.3 in the placebo groups. Standardized change
scores were greater for ginkgo than for placebo, with
SMD = -0.58 (95% CI -1.14; -0.01, z = 2.01, N = 7, p =
0.04) (Figure 2). However, heterogeneity was substantial
(c
2 = 178.92, I
2 = 97%).
Six studies with separate analyses for patients with
Alzheimer’s disease could be included for the subgroup
evaluation. For the Alzheimer subgroup, the standar-
dized change scores (ADAS-cog or SKT) were greater
for ginkgo than for placebo, with SMD = -0.63 (95%
CI -1.16; -0.10, z = 2.35, N = 6, p = 0.02). Heterogene-
ity remained high also in this subgroup (c
2 = 95.96,
I
2 = 95%).
Activities of daily living (ADLs)
In eight of the nine included studies, ADLs were evalu-
ated. Three studies [2,30,33] used the GERRI, one study
used the Nürnberger Alters-Alltagsaktivitätenskala
(NAA, self-assessed) [34], one trial used the Nürnberger
Alters-Beobachtungsskala (NAB, caregiver rated) [36],
one study used the ADL-IS (Ihl R, Bachinskaya N, Korc-
zyn AD, Tribanek M, Hoerr R, Napryeyenko O: Efficacy
and Safety of a Once-Daily Formulation of Ginkgo
biloba Extract EGb 761® in Dementia with Neuropsy-
chiatric Features. A Randomized Controlled Trial, sub-
mitted), and two studies used the GBS-ADL subscale
[32,35]. Change scores ranged from -0.1 to -0.05 in the
ginkgo groups and from -0.1 to 0.08 in the placebo
groups for GERRI, from -1.9 to -0.8 in the ginkgo
groups and 0.8 to 0.9 in the placebo groups for GBS-
ADL, from -0.2 to -0.16 in the ginkgo groups and 0 in
the placebo groups for ADL-IS, and from -1.0 to -0.8 in
the ginkgo groups and -0.4 in the placebo groups for
NAB. The change score was 1.4 in both the placebo
group and the ginkgo group in the study where the
NAA was used as outcome measure. There were no sta-
tistically significant differences in ADL change scores
between ginkgo and placebo, with SMD = -0.32 (95% CI
-0.66; 0.03, z = 1.77, N = 6, p = 0.08) (Figure 3). Again,
heterogeneity was substantial (c
2 = 83.27, I
2 = 92%).
For the Alzheimer subgroup (n = 5 trials) the standar-
dized change scores for ADL outcomes differed from
the whole group of dementia. In patients with
Table 1 Methodological quality of included studies
Study
Authors, date
Randomization/
allocation
concealment
Blinding of
patients/outcomes
assessment
Prior
estimate of
sample size
Withdrawals
per group
reported
ITT
analysis
adequate
Report of
measures of
precision
Data
inconsistencies
Funding
reported
Kanowski et al.
1996/2003
[29,36]
Yes/yes Yes/yes Partly
a Partly
b Yes Yes No No
Le Bars et al.
1997/2000
[30,37]
Yes/yes Yes/unclear Yes Yes Yes Yes No Yes
Maurer et al.
1997 [31]
Yes/unclear Yes/unclear No Yes No No No No
van Dongen
et al. 2000
[34,45]
Yes/yes Yes/yes Yes Yes No Yes Yes
c Yes
Schneider
et al. 2005 [33]
Yes/yes Yes/yes Yes Yes Yes Yes No Yes
Yancheva et al
2009 [35]
Yes/unclear Yes/unclear No Yes Yes Yes Yes Yes
Napryeyenko
et al. 2007 [32]
Yes/unclear Yes/unclear Yes Yes Yes Yes No Yes
McCarney
et al. 2008 [2]
Yes/yes Yes/yes Partly
a Yes Yes Yes No Yes
Ihl et al. 2009 Yes/yes Yes/yes No Yes Yes Yes No Yes
a: Less patients were included than planned; b: Drop-out rates were reported, but without reference to study arm; c: Multiple re-randomization schemes.
ITT = Intent-to-treat analysis.
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Page 6 of 12Alzheimer’s disease, there was a statistical superiority for
Ginkgo biloba compared to placebo (SMD = -0.44, 95%
CI -0.77; -0.12, z = 2.67, p = 0.008). Heterogeneity was
only slightly lower in this subgroup (c
2 = 32.34, I
2 =
88%).
Neuropsychiatric and behavioral symptoms
Neuropsychiatric symptoms were assessed in seven trials
( n=4N P I ,n=3H A M D ,n=1G D Sa n dn=1
MADRS). In some studies, depression scales were used
to exclude patients with clinically relevant depression. In
these studies, the investigators wanted to make clear
that effects on cognitive parameters could not be
explained by antidepressive effects. In two trials, which
included dementia patients with pre-existing neuropsy-
chiatric symptoms, there was a superiority of ginkgo
compared to placebo. Change scores ranged from -6.5
to -3.2 in the ginkgo groups and from 2.4 to 0 in the
placebo groups for NPI [32], Ihl R, Bachinskaya N,
Korczyn AD, Tribanek M, Hoerr R, Napryeyenko O:
Efficacy and Safety of a Once-Daily Formulation of
Ginkgo biloba Extract EGb 761® in Dementia with Neu-
ropsychiatric Features. A Randomized Controlled Trial,
submitted]. These differences were statistically signifi-
cant in both studies. However, four studies with non-
depressed and non-behaviorally disturbed patients did
not show any difference between ginkgo and placebo
[2,33,34,36] for neuropsychiatric and behavioral symp-
toms. Results for the Alzheimer subgroup did not differ
significantly from the whole dementia group.
Quality of life
Quality of life was assessed in three studies. In one
study, the QOL-AD scale was used as primary outcome
parameter [2]. Whereas two studies showed no differ-
ence between ginkgo and placebo in the 24-26 weeks
evaluation for PDS [33] and QOL-AD [2], one study (Ihl
R ,B a c h i n s k a y aN ,K o r c z y nA D ,T r i b a n e kM ,H o e r rR ,
Napryeyenko O: Efficacy and Safety of a Once-Daily
Formulation of Ginkgo biloba Extract EGb 761® in
Dementia with Neuropsychiatric Features. A Rando-
mized Controlled Trial, submitted) yielded a statistically
significant superiority of ginkgo in the improvement of
quality of life compared to placebo. There was an
improvement of 3.4 points in the DEMQOL-proxy scale
for the ginkgo group compared to a 1.4 improvement in
the placebo group.
Side effects
Discontinuation rates due to side effects varied from 1%
to 6% in the ginkgo groups and from 0 to 8% in the pla-
cebo groups. We could not find any differences between
the pooled groups in side effects and discontinuation
due to side effects.
Sensitivity analysis
Response was defined as an improvement of SKT or
ADAS-cog sores by ≥ 4 points [36,37], improvement of
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Page 7 of 12SKT by at least 3 points [32,34], Ihl R, Bachinskaya N,
Korczyn AD, Tribanek M, Hoerr R, Napryeyenko O:
Efficacy and Safety of a Once-Daily Formulation of
Ginkgo biloba Extract EGb 761® in Dementia with Neu-
ropsychiatric Features. A Randomized Controlled Trial,
submitted], improvement in GERRI [30], NPI improve-
ment of ≥ 4 points [2], Ihl R, Bachinskaya N, Korczyn
AD, Tribanek M, Hoerr R, Napryeyenko O: Efficacy and
Safety of a Once-Daily Formulation of Ginkgo biloba
Extract EGb 761® in Dementia with Neuropsychiatric
Features. A Randomized Controlled Trial, submitted],
much or very much improvement in the Clinical Global
Impression Scale (CGI) [31,36], or an improvement or
no change in the Clinical Global Impression of Change
Scale (CGIC) [33]. These variations in the response defi-
nitions limit the validity of this outcome measure, and
we decided not to evaluate response rates.
In one study [2], participants were allowed to con-
tinue a stable intake of cholinesterase inhibitors. This
led to one third of participants being prescribed such
substances. Furthermore, ginkgo was allowed to be
taken until two weeks before the baseline evaluation
(cholinesterase inhibitors intake: placebo 10%; ginkgo
25%) thus contributing to a possible spill-over effect
into the treatment phase. For most outcome parameters
there were no post-baseline-scores but only adjusted
differences in means available. Therefore, this study was
not included into meta-analyses. Removing one further
trial with only 30% of patients with a diagnosis of
dementia [34] did not significantly change our results.
After excluding this study, the SMD for cognition was
-0.66 (95% CI -1.29; -0.03, z = 2.06, N = 6, p = 0.04),
the SMD for ADLs was -0.37 (95% CI -0.76; 0.01, z =
1.88, N = 5, p = 0.06), and the RR for response was
Figure 3 ITT/LOCF change scores for activities of daily living outcomes by individual trial and pooled standardized mean difference
compared with placebo.
Figure 2 ITT/LOCF change scores for cognition outcomes (ADAS-cog, SKT) by individual trial and pooled standardized mean
difference compared with placebo.
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Page 8 of 121.85 (95% CI 1.17; 2.56, z = 2.93, N = 6, p = 0.009) for
the group of all dementias. In all cases, heterogeneity
remained high (I
2 above 80%).
A funnel plot of standard errors of log RRs (for
response) against log RRs showed a symmetrical distri-
bution with no evidence of publication bias. In the high
dosage group (240 mg Ginkgo biloba), the effect was
higher than in the low-dosage group (120 mg Ginkgo
biloba) in all outcome domains. For 120 mg Ginkgo
biloba, only one study [37] showed an advantage in cog-
nition and ADLs compared to placebo.
In the only head-to-head trial with 96 participants,
there was no difference after 22 weeks between Ginkgo
biloba 240 mg, donepezil 10 mg and the combination
treatment in any outcome parameter (SKT, NPI, GBS-
ADL, HAMD and neuropsychological tests).
Discussion
This review was performed because the efficacy and
effectiveness of Ginkgo biloba in dementia treatment
has been an issue of controversy against a background
of an increasing individual and societal burden due to
these disorders, and given only moderate effects of cho-
linesterase inhibitors and memantine [38,39]. With only
symptomatic treatments available, the clinical relevance
of all anti-dementia drugs would be to improve cogni-
tive and neuropsychological symptoms and activities of
daily living and/or to delay deterioration.
We found a statistically significant advantage of
Ginkgo biloba compared to placebo in improving cogni-
tion for the whole group of patients with Alzheimer’s
disease, vascular or mixed dementia. Regarding activities
of daily living, there was no significant difference for the
whole dementia group. However, in the subgroup of
patients with Alzheimer’s disease, the advantage of
Ginkgo biloba compared to placebo was statistically sig-
nificant. The benefit of Ginkgo biloba in overall
response rates was quite robust when all response defi-
nitions of the studies were accepted. However, the avail-
able response definitions differed considerably.
Therefore, we did not pool the results.
There was no consistent evidence of a benefit of
Ginkgo biloba in the treatment of neuropsychiatric
symptoms. However, the presence of psychological or
behavioral symptoms in dementia may be an effect
modifier. Two studies that included patients with neu-
ropsychiatric features yielded a clinically relevant effect
in this outcome domain. Based on our results, no solid
conclusions can be given for quality of life. Subgroup
analyses showed that a dosage of 240 mg of ginkgo
might be necessary to yield clinically relevant effects.
According to the evaluated studies, Ginkgo biloba
extract seems to be well tolerated with rates of adverse
effects and study withdrawals not being different
between medication and placebo. Nevertheless, it has to
be taken into account that randomized controlled trials
are not suitable to evaluate rare events and medication
interactions. The included studies were undertaken with
the standardized extract EGb 761®. However, other
ginkgo extracts and ginkgo-containing products may be
associated with different side effects. During intake of
EGb 761®, mild gastro-intestinal symptoms, headache,
dizziness or allergic skin reactions have occasionally
been reported. Single cases of bleeding, e.g. intracranial
haemorrhage, have been reported in the context of an
intake of Ginkgo biloba preparations. However, some of
these products concerned were of unknown origin and
quality, some were multi-ingredient products, and in
most instances anti-platelet agents or anticoagulants
were taken in addition. A review of controlled studies
indicated that the ginkgo extract EGb 761® does neither
influence blood clotting nor bleeding time nor signifi-
cantly potentiates the effects of anticoagulant or anti-
platelet drugs [40]. In addition, a systematic review of
case reports concluded that the clinical evidence for
Ginkgo biloba causing bleeding is far from compelling
[41,42].
We included efficacy as well as effectiveness studies in
a variety of settings and regions where different addi-
tional psychosocial treatments were offered. In addition,
in recent years the availability of cholinesterase inhibi-
tors and memory clinics may have influenced the way
dementia is seen and treated. With cholinesterase inhi-
bitors being established treatments, it has become more
difficult to run placebo- or actively controlled ginkgo
trials in Western countries. The larger effect sizes in the
Eastern European studies [[32], Ihl R, Bachinskaya N,
Korczyn AD, Tribanek M, Hoerr R, Napryeyenko O:
Efficacy and Safety of a Once-Daily Formulation of
Ginkgo biloba Extract EGb 761® in Dementia with Neu-
ropsychiatric Features. A Randomized Controlled Trial,
submitted] may indicate a higher differential efficacy of
Ginkgo biloba compared to placebo in a setting with
less specialized dementia care and less availability or
reimbursement of anti-dementia drugs. These two stu-
dies were the ones with the highest effect sizes for cog-
nition and activities of daily living outcomes and had
extremely low drop-out rates. Therefore, the higher
effect sizes in these studies might be a consequence of
lower drop-out rates and less influence of statistical
assumptions necessary to calculate last-observation-car-
ried-forward analyses. In addition, treatment can only
work optimally in compliant patients staying in the
study for the whole follow-up period. When more peo-
ple drop out of the treatment arm, this would lead to an
underestimation of the effect size of the intervention.
In a situation where the clinical significance of the
effects of anti-dementia drugs is increasingly questioned,
Weinmann et al. BMC Geriatrics 2010, 10:14
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Page 9 of 12and neither empirical data nor a consensus on minimally
clinically important differences in outcome parameters is
available [43], it is difficult to assess if the moderate
effects of ginkgo on cognition and ADLs make a differ-
ence for the patients in the long run. The validity and
reliability of clinical endpoints remain unclear with some
early trials using outcomes that would not be accepted
for modern studies. Furthermore, there was only one
study with a 52-week-follow-up which showed a small
but statistically significant advantage in cognition and
daily activities. The effects did not differ in magnitude
from the 26-week results. On the other hand, even a
short follow-up time of 12 weeks was sufficient to sepa-
rate ginkgo from placebo in one study [31]. This indicates
that the duration of the study and the setting as well as
methodological factors may be stronger outcome modi-
fiers than the effects of the medication itself.
With Ginkgo biloba being prescribed for a variety of
indications, external validity and generalisability of study
results to the target population is of utmost importance.
Using criteria for external validity assessment as proposed
by Bornhöft et al. [44], we realized that none of the studies
considered all those criteria. Some studies focused on the
efficacy of ginkgo and tried to assure high internal validity
with low selection, performance, detection and attrition
bias [33], Ihl R, Bachinskaya N, Korczyn AD, Tribanek M,
Hoerr R, Napryeyenko O: Efficacy and Safety of a Once-
Daily Formulation of Ginkgo biloba Extract EGb 761® in
Dementia with Neuropsychiatric Features. A Randomized
Controlled Trial, submitted]. In these studies, patients
with somatic or psychiatric comorbidity were excluded,
and other medications were not allowed. This may limit
the generalisability of the study results, although in most
of the studies included in this review, the setting reflected
the everyday conditions with most patients being treated
by outpatient clinics or practice-based physicians. One
study was performed only with persons living at old peo-
ple’s homes in the Netherlands and had an over-represen-
tation of the very old [34,45]. This may have contributed
to the lack of ginkgo effectiveness versus placebo. Other
studies were community-based pragmatic randomized
trials with substantial clinical relevance. For example, in
the McCarney et al. study [2], patients were included by
general practitioners. The very pragmatic design, together
with insufficient statistical power, however, may limit
internal validity as many of the included patients were
treated concurrently with cholinesterase inhibitors, which
were allowed to be continued in both study arms. This
may have led to a ceiling effect and the dilution of a signif-
icant effect [5]. A high external validity may therefore
compromise internal validity, particularly in those cases
where study designs reflect everyday conditions but fail to
control other influences on the outcomes. As Bornhöft et
al. note [46], in most ginkgo studies external validity has
not sufficiently been addressed. With evidence of a consid-
erable influence of contextual factors also in dementia
treatment, it is probable that trial participation itself
improves outcomes [47] and modifies the effects of medi-
cation. Therefore, it seems important to keep study condi-
tions as close to the clinical reality.
Our results are consistent with the Cochrane data
indicating a small advantage for ginkgo compared with
placebo at 12 and 24 weeks in dementia [7]. However,
we did not include trials where patients did not receive
a validated dementia diagnosis. Due to our inclusion
criteria, the overall methodological quality of studies
was higher than in the Cochrane Review, which
included some older studies without validated demen-
tia diagnoses, less rigorous randomization and alloca-
tion schemes and, consequently, a higher risk of bias.
In addition, we identified and included three recently
performed trials. Two of these trials showed a consid-
erable superiority of ginkgo in mild to moderate
dementia. This may have contributed to the differences
between ours and previous reviews. Contrary to pre-
vious reviews, we pooled the values of different out-
comes scales of the same domain for meta-analysis (e.
g. ADAS-cog and SKT for cognition). Given the pau-
city of studies using the same outcome scales, we felt
that this was justified in order to increase the power of
the meta-analysis.
Although there is some evidence of a Ginkgo biloba
mode of action through mitochondrial stabilization and
improvement of cerebral energy mechanism [48,49] in
addition to hemodynamic effects, there is no consistent
picture how this substance may alleviate dementia
symptoms. However, this is also true for cholinesterase
inhibitors.
Despite a considerable heterogeneity not fully
explained by dementia type or ginkgo dosage, we think
that ginkgo may be of benefit for a certain but unknown
proportion of dementia patients. Against this back-
ground and in analogy with dementia prevention [3,50],
it may be advisable to run a major multicenter study for
dementia treatment to definitively answer the question
of ginkgo effectiveness for different dementia subgroups
in advanced health care systems. Treatment and setting
should reflect everyday conditions as much as possible
without compromising internal validity. We think that
the hitherto gained results justify both symptomatic
treatment of dementia and further research, as differen-
tial effects for Alzheimer’s and vascular dementia are
obvious and ginkgo is carried on being used as a com-
plementary therapy in these disorders.
Conclusion
We found a statistically significant advantage of Ginkgo
biloba compared to placebo in improving cognition for
Weinmann et al. BMC Geriatrics 2010, 10:14
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vascular or mixed dementia. Regarding activities of daily
living, there was no significant difference for the whole
group. However, in the subgroup of patients with Alz-
heimer’s disease, there was a statistically significant
advantage of Ginkgo biloba compared to placebo. In a
situation, where the clinical significance of the moderate
effects of cholinesterase inhibitors and memantine as
symptomatic treatments is increasingly been questioned,
ginkgo biloba may not be an inferior treatment option
for a considerable number of people with mild or mod-
erate dementia. However, direct comparisons are lack-
ing. A major multicenter study to compare the relative
effectiveness of Ginkgo biloba and cholinesterase inhibi-
tors for different dementia subgroups appears justified.
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